Skip to main content
. Author manuscript; available in PMC: 2021 Feb 4.
Published in final edited form as: J Am Coll Cardiol. 2020 Feb 18;75(6):620–628. doi: 10.1016/j.jacc.2019.11.059

CENTRAL ILLUSTRATION. Cardiovascular Events in Pivotal Cancer Trials.

CENTRAL ILLUSTRATION

(A) Proportional frequency of incident reported cardiovascular disease(CVD)events during cancer trial follow-up, compared with reported contemporary nontribal population estimates (19–27) Plots stratified by CVD event types (hypertension not shown to due to high variation in rates based on drug type). (B) Reported versus observed cumulative CVD incidence rates, depicted in events per 100,000 person-years of available follow-up. Estimates reflect major adverse cardiovascular events from supporting anticancer trials compared with observed rates in a similar-aged contemporary population. *There were zero events reported for myocarditis